News and Blog

Life gets better when we enter our "golden years" and retire, doesn’t it?  Not necessarily. Because we are living longer, we face the possibility of living with an age-related chronic disease. Cancer, diabetes, and heart disease top the list of conditions we have the potential to acquire as we age.

The Moffitt Morsani Molecular Laboratory, located within the Moffitt Cancer Center, announced today that it has launched a new clinical NGS assay, Solid Tumor Actionable Result, or STAR. STAR is based off of the Illumina TruSight Tumor 170 panel that interrogates 170 genes thought to be drivers in the development of solid tumors.

PierianDx will be highlighting germline features of its genomics technology platform the American College of Medical Genetics and Genomics (ACMG) annual meeting April 10-14 in Charlotte, North Carolina.

When CMS initiated a national coverage analysis for NGS-based testing for advanced cancer on November 30, 2017, it stirred up a lot of debate among the leaders in precision medicine, and more specifically, PierianDx’s partner network of academic medical centers, cancer centers and health systems. For our customers, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the proposed policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.

We are excited to attend the upcoming Precision Oncology Experimental Therapeutics (POET) Congress in Calgary, Alberta the first week in April. We will have an opportunity to collaborate with precision medicine luminaries from Canada and around the world on how best to transition novel biomarker research into routine cancer management.

On April 5 and 6 oncology leaders will convene in Calgary, Alberta to participate in the 2nd International Precision Oncology and Experimental Therapeutics (POET) Congress. The annual meeting supports the education arm of the POET Congress research program that works to incorporate novel biomarker-driven phase I clinical trials research into practical routine cancer management.  The goal of the congress is to accelerate education and knowledge dissemination of the most current novel interrogative-based approaches that drive precision oncology forward.

Genetic diseases are the leading cause of death for infants in North America, affecting an estimated 4 percent of newborns. In MIT Technology Review, Rady Children’s Hospital in San Diego showcases the “new wave of precision medicine” that uses genetics to determine life saving drug options for newborns.

Laura J. Tafe, MD, associate professor of pathology and laboratory medicine at Geisel School of Medicine at Dartmouth, and assistant director of the Laboratory for Clinical Genomics and Advanced Technologies, Dartmouth-Hitchcock Medical Center, discusses a case of ALK-rearranged lung cancer, which was the subject of a multidisciplinary molecular tumor board presented last fall at the annual CAP meeting.

While healthcare continues to improve, advances in technologies and treatments have also made it more complex. It’s estimated that nearly 100,000 patients die every year due to medical errors [1]. And consider this: medical errors due to misdiagnosis account for up to 17% of all adverse medical events [2].

by Brad Herrick, PierianDx

PierianDx, the leading genomics technology company that enables precision medicine programs and molecular testing for healthcare organizations, announced today a partnership with Cancer Genetics, Inc. (CGI) (Nasdaq: CGIX) to provide a comprehensive precision oncology testing and workflow solution to enhance patient care. CGI is a leader in enabling precision medicine for oncology through molecular markers and diagnostics.

PierianDx, the leading genomics technology company that enables precision medicine, announced today a full range of expanded services to support adoption of the company’s enterprise software platform, the Clinical Genomics WorkSpace (CGW).